drugset
drugset / Trial / NCT04840901

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

NCT04840901 ↗

Phase 1 Completed 242 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days.

Timeline

Start
2021-06-02
Primary completion
2022-02-11
Completion
2022-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody 125 mg/ml Subcutaneous

Indications

No indication recorded.